A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

  • Huntington's Disease
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • Aachen
  • Aarhus
  • Aberdeen
  • ADC
  • AEB
  • Amherst
  • Angers
  • Auckland
  • Badajoz
  • Baltimore
  • Barakaldo
  • Barcelona
  • Basel
  • Berlin
  • Birmingham
  • Bochum
  • Bologna
  • Bonn
  • Boston
  • Buenos Aires
  • Burgos
  • Cambridge
  • Cardiff
  • Chicago
  • Christchurch
  • Clayton
  • Créteil
  • Edmonton
  • Englewood
  • Erlangen
  • Firenze
  • Gdańsk
  • Genova
  • Glasgow
  • Groningen
  • Halifax
  • Houston
  • Innsbruck
  • Kashiwazaki
  • Kazan
  • Kirkland
  • Kodaira
  • Kraków
  • Krasnoyarsk
  • København
  • La Jolla
  • Lazio
  • Leeds
  • Leiden
  • Lille
  • Lo Espejo
  • London
  • Lübeck
  • Madrid
  • Manchester
  • Marseille
  • Milano
  • Montpellier
  • Montréal
  • Moscow
  • Moskva
  • muri-bei-bern
  • Münster
  • Nashville
  • New York
  • Okayama
  • Osaka
  • Ottawa
  • Oxford
  • Palo Alto
  • Paris
  • Parkville
  • Pasadena
  • Phoenix
  • Pittsburgh
  • Sacramento
  • Sagamihara
  • Salt Lake City
  • Salzburg
  • San Giovanni Rotondo
  • Sevilla
  • Sheffield
  • Southampton
  • St. Louis
  • Tampa
  • Toronto
  • Toulouse
  • Ulm
  • València
  • Vancouver
  • Warszawa
  • Washington
  • Wellington
  • Westmead
  • 横浜市
Trial Identifier:

NCT03761849 BN40423

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD).

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT03761849 , BN40423 Trial Identifier
      RO7234292, Placebo Treatments
      Huntingtons Disease Condition
      Official Title

      A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

      Eligibility Criteria

      All Gender
      ≥25 Years & ≤ 65 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Manifest HD diagnosis, defined as a DCL score of 4
      • Independence Scale (IS) score >= 70
      • Genetically confirmed disease by direct DNA testing with a CAP score >400
      • Clinical assessment to ensure individual has intact functional independence at baseline to maintain self-care and core activities of daily living (ADLs).
      Exclusion Criteria
      • Any serious medical condition or clinically significant laboratory, or vital sign abnormality or claustrophobia at screening that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
      • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study drug

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now